C4 Therapeutics (CCCC) Stock Overview
A clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CCCC Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
C4 Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.51 |
| 52 Week High | US$5.17 |
| 52 Week Low | US$1.69 |
| Beta | 2.95 |
| 1 Month Change | -10.00% |
| 3 Month Change | -10.00% |
| 1 Year Change | 31.95% |
| 3 Year Change | 57.40% |
| 5 Year Change | -92.97% |
| Change since IPO | -86.23% |
Recent News & Updates
C4 Therapeutics: Priced For Perfection Ahead Of 2027 Cemsidomide Readouts
Summary C4 Therapeutics is rated Hold, with valuation hinging on the Phase 2 success of its lead asset, cemsidomide. CCCC holds $300.4 million in cash, providing runway through late 2028 and supporting ongoing clinical and partnered programs. The calculated fair value per share is $3.32, below the current $3.71 price, reflecting significant risk if cemsidomide fails. Phase 2 MOMENTUM trial data in late 2027 is the critical catalyst; success could raise fair value to $5.32 per share. Read the full article on Seeking AlphaEarnings Beat: C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
C4 Therapeutics, Inc. ( NASDAQ:CCCC ) just released its latest quarterly results and things are looking bullish...Recent updates
Shareholder Returns
| CCCC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.6% | -5.9% | -2.2% |
| 1Y | 32.0% | 34.6% | 13.1% |
Return vs Industry: CCCC underperformed the US Biotechs industry which returned 34.6% over the past year.
Return vs Market: CCCC exceeded the US Market which returned 13.1% over the past year.
Price Volatility
| CCCC volatility | |
|---|---|
| CCCC Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CCCC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CCCC's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 104 | Andrew Hirsch | www.c4therapeutics.com |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration.
C4 Therapeutics, Inc. Fundamentals Summary
| CCCC fundamental statistics | |
|---|---|
| Market cap | US$418.29m |
| Earnings (TTM) | -US$101.42m |
| Revenue (TTM) | US$35.04m |
Is CCCC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CCCC income statement (TTM) | |
|---|---|
| Revenue | US$35.04m |
| Cost of Revenue | US$4.79m |
| Gross Profit | US$30.25m |
| Other Expenses | US$131.67m |
| Earnings | -US$101.42m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.82 |
| Gross Margin | 86.34% |
| Net Profit Margin | -289.44% |
| Debt/Equity Ratio | 0% |
How did CCCC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/11 01:38 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
C4 Therapeutics, Inc. is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | Barclays |
| Chi Meng Fong | BofA Global Research |
| Leah Rush Cann | Brookline Capital Markets |